Characterization of a new, short-acting and specific inhibitor of type A monoamine oxidase.
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D001679:Biogenic Amines / Q000378:metabolism; D001921:Brain / Q000201:enzymology; D001923:Brain Chemistry / Q000187:drug effects; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D008099:Liver / Q000201:enzymology; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000378:metabolism; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D012702:Serotonin Antagonists; D013574:Synaptosomes / Q000378:metabolism; D014191:Tranylcypromine / Q000494:pharmacology
D001679:Biogenic Amines; D008996:Monoamine Oxidase Inhibitors; D010880:Piperidines; D012702:Serotonin Antagonists; D015102:3,4-Dihydroxyphenylacetic Acid; D014191:Tranylcypromine; D008734:Methoxyhydroxyphenylglycol; D006897:Hydroxyindoleacetic Acid; C038213:brofaromine